Clinical efficacy of SARS-CoV-2 Omicron-neutralizing antibodies in immunoglobulin preparations for the treatment of agammaglobulinemia in patients with primary antibody deficiency
Makaleler > Tam Makale · 2024
Yazarlar: Michael Karbiener, Gerhard Kindle, Isabelle Meyts, Mikko R.J. Seppänen, Fabio Candotti, Marta Kamieniak, Reinhard Ilk, Thomas R. Kreil, Markus G. Seidel, Dalia Abd Elaziz, Lofty M. Abdelkader Sohilla, Avigaelle Abitbol, Abolhassani Hassan, Lalash Abrahim, Mohamed Abuzakouk, Moussouni Nabila Achir, Veronica Afonso, Philipp Agyeman, Martina Ahlmann, Alessandro Aiuti, Abla Akl, Güzide AKSU, Kim Albers, Kim Albers, Michael Albert, Meda Diana Alecsandru, Olga Aleinikova, Svetlana Aleshkevich, Luis Allende, Mickael Alligon, Zoe Allwood, Manrique de Lara Laia Alsina, Daniela Ambrosch‐barsoumian, Lisa Ameshofer, Kenza Amour, Evrim Anadol, Ariharan Ananthachagaran, Chantal Andriamanga, Julia Andris, Karin Andritschke, Karin Andritschke, Federica Angelini, Tobias Ankermann, Katrin Apel, Siamak Arami, Ömür Ardeniz, Peter Arkwright, Karina Arnold, Rudolf Ascherl, Najla Assam, Nurit Assia-Batzir, Faranaz Atschekzei, Sybille Aumann, Volker Aumann, Magnus Aurivillius, Bernd Ausserer, Tadej Avcin, Sezin Aydemir, Emel Aygören-Pürsün, Deniz Cagdas Ayvaz, Carolina Brito de Azevedo Amaral, Chiara Azzari, Lo Babacar, Perrine Bach, Sophie Bachmann, Peter Bader, Peter Bader, Shahrzad Bakhtiar, Renate Bancé, Catherine Bangs, Merlin Simsen Baratault, Katerina Barfusz, Safa Baris, Isil B. Barlan, Michaela Bartsch, Helge Baumann, Ulrich Baumann, Veronika Baumeister, Helen Baxendale, Suzanne Bazen, Beatrice Beaurain, Julien Beauté, Norbert Beck, Brigitta Becker, Christian Becker, Christian Becker, Uta Behrends, Uta Behrends, Renata Beider, Rita Beier, Luisa Belke, Sven Bellert, Bernd H. Belohradsky, Bernd H. Belohradsky, Lilia Ben Slama, Lilia Ben Slama, Aouatef Ben-Bouzid, Thamila Berdous-Samed, Jan Bergils, Anna Berglöf, Necil KÜTÜKÇÜLER
JOURNAL OF MEDICAL VIROLOGY, SCI Expanded İndekslerine Giren Dergi, Uluslararası, Scopus, 2024, cilt 96, ss e29738-e29738
DOI: 10.1002/jmv.29738
Özet
Immunocompromised individuals are at significantly elevated risk for severe courses of coronavirus disease 2019 (COVID-19). In addition to vaccination, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralizing antibodies (nAbs) have been applied throughout the pandemic, with time of treatment onset and potency against the currently prevailing virus variant identified as relevant factors for medical benefit. Using data from the European Society for Immunodeficiencies (ESID) registry, the present study evaluated COVID-19 cases in three groups of patients with inborn errors of immunity (IEI; 981 agammaglobulinemia patients on immunoglobulin replacement therapy (IGRT); 8960 non-agammaglobulinemia patients on IGRT; 14 428 patients without IGRT), and the neutralizing capacity of 1100 immunoglobulin lots against SARS-CoV-2 (“Wuhan” and Omicron strains), throughout 3 years. From the first (2020/2021) to the second (2021/2022) cold season, i.e., during the virus drift to the more contagious Omicron variants, an increase in case numbers was recorded that was comparable (~2- to 3-fold) for all three study groups. During the same period, immunoglobulin lots showed a profound nAb increase against the archetypal SARS-CoV-2 strain, yet only low levels of Omicron nAbs. Notably, shortly before the third (2022/2023) cold season, Omicron-neutralizing capacity of released immunoglobulin lots had plateaued at high levels. From the second to the third cold season, COVID-19 cases dropped markedly. While a ~6-fold case reduction was recorded for the groups of non-agammaglobulinemia patients on IGRT and IEI patients not receiving IGRT, the decline was ~30-fold for the group of agammaglobulinemia patients on IGRT. These findings suggest a substantial COVID-19-protective effect of IGRT, at least for distinct groups of antibody-deficient patients.